| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:853.)
© 2004 American Heart Association, Inc.
Original Contributions |
From Pharmacology and Clinical Pharmacology (M.B.H.) and Clinical Neuroscience (S.S., H.S.M.), St Georges Hospital Medical School, London, and Clinical Sciences, Warwick Medical School (D.R.J.S.), University of Warwick, Coventry, UK.
Correspondence to Donald R.J. Singer, Professor of Clinical Pharmacology, Clinical Sciences, Warwick Medical School (LWMS), University of Warwick, Coventry CV4 7AL UK. E-mail donald.singer{at}warwick.ac.uk
Background and Purpose Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is characterized by ultrastructural abnormalities in small cerebral and systemic vessels. We assessed vasomotor function in systemic small arteries in CADASIL.
Methods We studied 10 CADASIL patients and 10 control subjects. Resistance arteries isolated from gluteal biopsies were mounted on small-vessel myographs, and concentration responses were determined for vasoconstrictors (noradrenaline, angiotensin II, and endothelin-I) and vasodilators (acetylcholine, bradykinin, spermine-NONOate, and nifedipine). Maximum data are shown as percent potassium contraction.
Results There was reduced potency for noradrenaline in CADASIL (CADASIL [38 arteries]: EC50, 240 nmol/L; control subjects [27 arteries]: EC50, 100 nmol/L; 2-way analysis of variance, F=9.76, P=0.002). Maximum response to angiotensin II was greater in CADASIL (120±8% versus 97±5% in control subjects; F=4.28, P=0.043). Tachyphylaxis to angiotensin II occurred in all control subjects studied but in only 3 of 9 CADASIL subjects (P=0.011, Fishers exact test). Vasodilation was similar in CADASIL patients compared with control subjects for endothelium-dependent dilators (acetylcholine and bradykinin) and endothelium-independent dilators (spermine-NONOate and nifedipine).
Conclusions These results suggest a selective systemic microvascular vasoconstrictor abnormality in CADASIL in noradrenaline and angiotensin II pathways that is not explained by vasodilator impairment in endothelium or vascular smooth muscle. This could have important implications for prophylaxis and treatment of CADASIL.
Key Words: angiotensins arteries CADASIL muscle, smooth noradrenaline
This article has been cited by other articles:
![]() |
A. Stenborg, H. Kalimo, M. Viitanen, A. Terent, and L. Lind Impaired Endothelial Function of Forearm Resistance Arteries in CADASIL Patients Stroke, October 1, 2007; 38(10): 2692 - 2697. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rufa, M. T. Dotti, M. Franchi, M. L. Stromillo, G. Cevenini, S. Bianchi, N. De Stefano, and A. Federico Systemic Blood Pressure Profile in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Stroke, December 1, 2005; 36(12): 2554 - 2558. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Haritunians, T Chow, R P J De Lange, J T Nichols, D Ghavimi, N Dorrani, D M St Clair, G Weinmaster, and C Schanen Functional analysis of a recurrent missense mutation in Notch3 in CADASIL J. Neurol. Neurosurg. Psychiatry, September 1, 2005; 76(9): 1242 - 1248. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dubroca, P. Lacombe, V. Domenga, J. Maciazek, B. Levy, E. Tournier-Lasserve, A. Joutel, and D. Henrion Impaired Vascular Mechanotransduction in a Transgenic Mouse Model of CADASIL Arteriopathy Stroke, January 1, 2005; 36(1): 113 - 117. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |